Pityriasis rubra pilaris occurring after vaccination with diphtheria-pertussis-tetanus and oral poliovirus vaccines

Pityriasis rubra pilaris‐like eruption following administration of the BNT163b2 (Pfizer–BioNTech) mRNA COVID‐19 vaccine

“…There have been cases of postvaccination PRP following inoculation with traditional viral vector vaccines such as the diphtheria and influenza vaccines. 4 To our knowledge, this is the first reported case of PRP following administration of the BNT163b2 COVID-19 vaccine. If PRP occurs after the first dose, then a discussion with the patient, weighing the risks and benefits including worsening of disease compared with the possibility of severe disease/death from COVID-19 should be undertaken.…”

An old entity, a new trigger: Post COVID-19 vaccine pityriasis rubra pilaris

“…The trigger mechanism of post-vaccination PRP may be immunological or infectious. Previous reports of disease occurrence have been associated with diphtheria-pertussis-tetanus, anti-influenza, measlesmumps-rubella, and the oral polio vaccine [2]. Cases described had lesions two to three weeks after receiving the vaccine of which two were in children under 2 years and the other two were in adult females.…”

“…Cases described had lesions two to three weeks after receiving the vaccine of which two were in children under 2 years and the other two were in adult females. In the fourth case a 19-month-old child received the DPT vaccine and oral polio vaccine as a part of routine immunisation and two weeks later developed lesions that resolved in topical therapy in five months [2]. No data was provided on any of the case reports on the recurrence of subsequent vaccination.…”

Pityriasis rubra pilaris potentially triggered by messenger RNA–1273 COVID vaccine

“…Two other cases involved infants, ages 19 months and 17 months, who developed PRP 2 weeks after diphtheria, tetanus, and pertussis and poliovirus vaccinations and 2 weeks after the measles, mumps, and rubella vaccination, respectively. 5 Relevant to the current case, 2 cases have been reported following vaccination for COVID-19 with ChAdOx1 nCoV-19 vaccines. Specifically, a 72-year-old man developed PRP 3 weeks after the initial Covishield vaccination, and a 63-year-old woman developed PRP 9 days after the initial Vaxzevria vaccination.…”

“…PRP often presents sporadically but can follow an acute illness or be medication induced. 5 Rare case reports implicate vaccines as a trigger. Two reported cases involved adult women, ages 32 and 47, who developed PRP 10 days after receiving the diphtheria, tetanus, and pertussis vaccination and 18 days after the anti-influenza vaccination, respectively.…”